1. Adenoviruses as vaccine vectors;Tatsis;Mol Ther,2004
2. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19;Sadoff;N Engl J Med,2021
3. AstraZeneca AZD1222 clinical study group. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine;Falsey;N Engl J Med,2021
4. Étude D8110C00001. A phase III randomized, double-blind, placebo-controlled multicenter study in adults, to determine the safety, efficacy, and immunogenicity of AZD1222, a non-replicating ChAdOx1 vector vaccine, for the prevention of COVID-19. https://clinicaltrials.gov/ct2/show/NCT04516746 [Consulté le 12 décembre 2022. [1pp.].
5. ANSM. Enquête de pharmacovigilance du vaccin COVID-19 JANSSEN®. Rapport n°4: période du 09 juillet 2021 au 26 août 2021. https://ansm.sante.fr/uploads/2021/09/13/rapport-n4-janssen-final-09092021-vfa.pdf [Consulté le 12 décembre 2022 (38 pp.)].